Acute Myeloid Leukemia

Acute Myeloid Leukemia, commonly referred to as AML, is a type of cancer that starts in the bone marrow and affects white blood cells. This aggressive form of cancer can quickly spread to other parts of the body, including the lymph nodes, spleen, liver, and brain. AML is caused by the abnormal growth and accumulation of immature white blood cells, known as myeloid blasts. These blasts interfere with the normal production of healthy blood cells, leading to a decrease in the number of red blood cells, white blood cells, and platelets in the body. As a result, patients with AML may experience symptoms such as fatigue, weakness, infections, and bleeding. Treatment for AML typically involves a combination of chemotherapy, radiation therapy, and stem cell transplantation. However, new therapies such as targeted drug therapy and immunotherapy are also being developed. Research in hematology and oncology is essential to improve the understanding of the disease and develop new treatments. Scientists are investigating the genetic mutations that trigger AML, studying the microenvironment of the cancer cells, and testing new therapies in clinical trials. The Hematology Oncology Research Group is dedicated to advancing the understanding of AML and other types of cancers through interdisciplinary research. Their work not only has the potential to improve the prognosis for patients with AML but could also have implications for other types of cancers. By utilizing the latest scientific techniques and technologies to understand the disease, researchers can identify new strategies to treat AML and ultimately improve patient outcomes.